| scholarly article | Q13442814 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| Paul G. Richardson | Q87712102 | ||
| Melissa Ooi | Q89531124 | ||
| Jana Jakubikova | Q89681431 | ||
| Peter H Gorman | Q91117968 | ||
| Martin Clynes | Q92266724 | ||
| Jake E Delmore | Q117224718 | ||
| Constantine S Mitsiades | Q117224720 | ||
| Steffen Klippel | Q117224723 | ||
| P2093 | author name string | Robert O'Connor | |
| Justine Meiller | |||
| P2860 | cites work | Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis | Q28368354 |
| Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation | Q28478937 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein | Q33183490 | ||
| Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma | Q33288939 | ||
| Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications | Q33820610 | ||
| Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling | Q34124356 | ||
| Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis | Q35582713 | ||
| The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications | Q35912178 | ||
| The pharmacology of cancer resistance. | Q36861332 | ||
| New drugs for myeloma | Q36865500 | ||
| Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | Q36889961 | ||
| Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib | Q36902184 | ||
| Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. | Q37207049 | ||
| Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. | Q37863987 | ||
| The role of tumour-stromal interactions in modifying drug response: challenges and opportunities | Q38085500 | ||
| Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance | Q38325194 | ||
| NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells | Q38358712 | ||
| Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma | Q39773303 | ||
| Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 | ||
| Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. | Q39842390 | ||
| The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. | Q39878075 | ||
| In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies | Q39915376 | ||
| PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. | Q39959297 | ||
| Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp | Q40009361 | ||
| Activity of bortezomib in glioblastoma. | Q40187592 | ||
| Cell-cell contact mediated signalling - no fear of contact. | Q40292594 | ||
| Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). | Q40933385 | ||
| Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines | Q40947245 | ||
| Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A | Q41649455 | ||
| Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells | Q42909895 | ||
| The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications | Q43700541 | ||
| Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). | Q43885601 | ||
| Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma | Q44103318 | ||
| A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study | Q44158194 | ||
| The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications | Q44211035 | ||
| Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr | Q46898523 | ||
| P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. | Q52402350 | ||
| The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. | Q53530281 | ||
| Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. | Q53585037 | ||
| Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. | Q54005859 | ||
| P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. | Q54192269 | ||
| Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs) | Q58838535 | ||
| Acid phosphatase: endpoint for in vitro toxicity tests | Q70155179 | ||
| Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B | Q70903372 | ||
| Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells | Q71087693 | ||
| Characterization of marrow stromal (fibroblastoid) cells and their association with erythropoiesis | Q71474840 | ||
| Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study | Q71727922 | ||
| The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy | Q73042152 | ||
| Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors | Q80699766 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1357-1368 | |
| P577 | publication date | 2013-04-16 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias | |
| P478 | volume | 71 |
| Q47131929 | (Immuno)proteasomes as therapeutic target in acute leukemia |
| Q90317385 | A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma |
| Q36618001 | CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy |
| Q38932086 | Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters |
| Q27692033 | Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms |
| Q37688848 | Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors |
| Q92551431 | Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment |
| Q42022337 | Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients |
| Q39185604 | Mechanisms of Resistance in Multiple Myeloma |
| Q47804377 | MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. |
| Q89682913 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance |
| Q38845179 | Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines |
| Q37607909 | Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins |
| Q52783909 | Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers. |
| Q61799039 | Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis |
| Q91229404 | The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies |
| Q38152293 | The network of P-glycoprotein and microRNAs interactions |
| Q38200143 | The role of P-glycoprotein in drug resistance in multiple myeloma |
| Q38856951 | Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies |
| Q37171812 | Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling |
| Q47109683 | Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner |
| Q41699685 | Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells. |
| Q36216250 | Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells |
| Q35934993 | pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells |
Search more.